be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Tag: schizophrenia

Show search box

2015-02-17

Pierre Fabre initiates Phase IIa trials for a new drug for Schizophrenia

Pierre Fabre initiates Phase IIa trials for a new drug for Schizophrenia

A French multinational company Pierre Fabre Pharmaceuticals has announced a start of Phase IIa clinical trials for a new selective antagonist of dopamine D3 receptor called F17464 in patients suffering from schizophrenia. The major aim is to determine the effectiveness and assess safety of the drug d... Read more

Tags clinical trials , drug , Pierre Fabre , schizophrenia , F17464